LivingGLP1
parallel randomized trial

S003053

Design

Randomized
31
Start year
2011
Treatment
14 weeks, follow-up 14 weeks
Countries
Japan (7 sites)
Sponsor
Hokkaido Diabetes Clinical Research Organization (non industry)
Eligibility
T2D; age 20 to 75; HbA1c 7.4 to 10.5 percent; no atherosclerotic disease; no insulin

Conduct and analysis

Blinding
open label
Sequence generation
computer
Allocation concealment
not reported
Outcome adjudication
not reported
Primary estimand
not stated
Analysis population
randomized
Missing data

Arms

ArmTreatmentBackgroundRandomizedAnalyzedCompleted treatment
A1liraglutide
Liraglutide
metformin and or sulfonylurea or DPP-4 inhibitor; lifestyle: standard1616
A2Insulin glargine
Insulin glargine
metformin and or sulfonylurea or DPP-4 inhibitor; lifestyle: standard1515

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.
CharacteristicStatisticLiraglutide
A1
Insulin glargine
A2
agemean (years)61.159.5
agesd (years)8.312.3
bmimedian (kg/m2)26.625.8
bmiq1 (kg/m2)23.624.2
bmiq3 (kg/m2)29.928.2
hba1cmean (percent)8.68.7
hba1csd (percent)0.80.8
metformin usepercent10093.3
other dpp4i usepercent43.866.7
other malepercent75.046.7
other sulfonylurea usepercent87.580.0
sbpmean (mmHg)136.0126.4
sbpsd (mmHg)14.914.2

Results

4 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
HbA1c change (2 lines; O01)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
14A1change-1.20 percent-1.54 to -0.8616not stated; other; R0022481:Table 3
14A2change-0.65 percent-1.34 to 0.0315not stated; other; R0022481:Table 3
Systolic blood pressure change (2 lines; O05)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
14A1change0.3 mmHg-11.9 to 12.516not stated; other; R0022481:Table 3
14A2change4.9 mmHg-5.1 to 14.915not stated; other; R0022481:Table 3